Division of Hematology, Department of Hematology & Medical Oncology, Winship Cancer Institute of Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA.
Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.
The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias. Bosutinib has shown activity against all phases of resistant chronic myeloid leukemia that do not harbor the T315I or V299L ABL kinase domain mutations. Bosutinib is overall well tolerated; transient diarrhea is the most common side effect. This article summarizes the pharmacokinetics, pharmacodynamics, safety and efficacy of bosutinib for the treatment of Philadelphia chromosome-positive leukemias.
SRC-ABL 抑制剂博舒替尼是目前批准用于治疗费城染色体阳性白血病的五种酪氨酸激酶抑制剂之一。博舒替尼对不携带 T315I 或 V299L ABL 激酶结构域突变的耐药慢性髓性白血病的所有阶段均有活性。博舒替尼总体耐受性良好；最常见的不良反应是短暂性腹泻。本文总结了博舒替尼治疗费城染色体阳性白血病的药代动力学、药效学、安全性和疗效。
